Variant II beta-thalassemia Short Program Model Numbers 270-2103 (250 tests) and 270-2154 (500 te...
FDA Device Recall #Z-1537-2014 — Class II — April 8, 2014
Recall Summary
| Recall Number | Z-1537-2014 |
| Classification | Class II — Moderate risk |
| Date Initiated | April 8, 2014 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Bio-Rad Laboratories, Inc. |
| Location | Hercules, CA |
| Product Type | Devices |
| Quantity | 457 kits |
Product Description
Variant II beta-thalassemia Short Program Model Numbers 270-2103 (250 tests) and 270-2154 (500 tests), Bio-Rad Laboratories, Inc. in vitro diagnostic. The Variant II Hemoglobin testing system uses the principals of high performance liquid chromatography (HPLC) for the separation and determination of normal and abnormal hemoglobin.
Reason for Recall
There is an issue with the buffers which impacts the quantification of the Hemoglobin F peak. Calibration and Quality control are likely to fail if the affected lots are used.
Distribution Pattern
Worldwide Distrubution ; USA INCLUDING CA, NY, GA, NC, AL, NJ, CT, WA, NY, LA, Il, MA and Internationally to China, Australia, Canada, France, Great Britain, Hong Kong, Thailand, Singapore,and Brazil.
Lot / Code Information
Catalog number: 270-2103 (250 tests; Reorder pack lot number: 64005302, Expiration: 4/2015; Catalog number: 270-2154 (500 tests) Reorder pack lot number: 64005207, Expiration: 6/2015; 64004750, Expiration: 11/2015
Other Recalls from Bio-Rad Laboratories, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2515-2025 | Class II | Platelia Toxo IgM Catalog Number 26211 UDI Cod... | May 30, 2025 |
| Z-1572-2023 | Class II | BioPlex 2200 REF 665-2050, APLS IgM Pack, APLS ... | Feb 28, 2023 |
| Z-1377-2023 | Class II | BioPlex 2200, Anti-CCP Reagent Pack, REF 665-32... | Feb 21, 2023 |
| Z-1378-2023 | Class II | BioPlex 2200, Anti-CCP Calibrator Set, REF 663-... | Feb 21, 2023 |
| Z-0342-2023 | Class II | CMV IgM EIA, in vitro diagnostic. | Oct 19, 2022 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.